For Veterinarians

• FDA Informs Veterinarians about Important Labeling Changes to Critical Care Medications for People
• New Antiparasitic Drugs Needed for Small Ruminants
• What Veterinarians Should Tell Clients About Pain Control and Their Pets
• Conditional Approval Explained: A Resource for Veterinarians
• FDA Provides Equine Veterinarians with Important Information about TILDREN and OSPHOS for Navicular Syndrome in Horses
• A Microgram of Prevention is Worth a Milligram of Cure: Preventing Medication Errors in Animals
• Potassium Bromide: Is It Safe for Dogs?
• A Systematic Review of the Safety of Potassium Bromide in Dogs (JAVMA, Vol 240, No. 6, March 15, 2012) (PDF - 670KB)
• Concerns about marketed but unapproved animal drugs (JAVMA, Vol 240, No. 9, May 1, 2012) (PDF - 187KB)
• The Ins and Outs of Extra-Label Drug Use in Animals: A Resource for Veterinarians
• Antiparasitic resistance and grazing livestock in the United States (JAVMA, Vol 244, No. 9, May 1, 2014)

Letters issued to veterinarians by the FDA CVM alerting them to important information regarding approved new animal drugs and other veterinary products.

• VETORYL (trilostane) Capsules
• Phenylbutazone in Horses
• EQUIDONE (domperidone) Gel
• SucroMate Equine (deslorelin acetate)
• INCURIN (estriol) Tablets and PROIN (phenylpropanolamine hydrochloride) Chewable Tablets
• PRASCEND (pergolide mesylate) Tablets
• GONAbreed
• FACTREL
• Jerky Pet Treats
• Kinavet-CA1 (mastinib mesylate)

• Dear Doctor Letters
  Letters issued to veterinary medicine professionals by drug manufacturers alerting the professionals to important safety information.
• Adverse Drug Experience (ADE) Reports
  Adverse Drug Experience Reporting
• Risk Minimization Action Plans (RiskMAPs) for Approved Products